# Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
Canonical URL: https://biopharmsignal.com/news/ABOS/acumen-pharmaceuticals-to-participate-in-upcoming-investor-conferences-89b5c905
Ticker: ABOS
Company: Acumen Pharmaceuticals
Source: Acumen Pharmaceuticals
Published: 2026-09-02 20:00 EST
## Summary

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing...

## Article Body
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in the following upcoming investor conferences.

Cantor Global Healthcare Conference 2026

Date/Time: Fireside chat on Wednesday, September 9, 2026 at 3:55 p.m. ET

Citi’s 2026 Biopharma Back to School Conference

Date/Time: Fireside chat on Thursday, September 10, 2026 at 8:40 a.m. ET

The live webcasts may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.

About Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its lead investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. Acumen is also investigating a subcutaneous formulation of sabirnetug using Halozyme’s proprietary ENHANZE® drug delivery technology. Acumen is also collaborating with JCR Pharmaceuticals to develop an Enhanced Brain Delivery™ (EBD™) therapy for Alzheimer’s disease utilizing a transferrin-receptor-targeting blood-brain barrier-penetrating technology. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com .

Investors: Alex Braun abraun@acumenpharm.com

Media: ICR Healthcare AcumenPR@icrhealthcare.com
## Recent Company News
- 2026-09-02 20:00 EST — [Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/ABOS/acumen-pharmaceuticals-to-participate-in-upcoming-investor-conferences-89b5c905) — Source: Acumen Pharmaceuticals
- 2026-08-12 11:00 EST — [Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights](https://biopharmsignal.com/news/ABOS/acumen-pharmaceuticals-reports-second-quarter-2026-financial-results-and-busines-82f52001) — Source: Acumen Pharmaceuticals
- 2026-08-05 20:00 EST — [Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026](https://biopharmsignal.com/news/ABOS/acumen-pharmaceuticals-to-report-second-quarter-financial-results-on-august-12-2-464ebfdf) — Source: Acumen Pharmaceuticals
- 2026-07-15 11:30 EST — [Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ (EBD™) Program Data and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026](https://biopharmsignal.com/news/ABOS/acumen-pharmaceuticals-highlights-enhanced-brain-delivery-ebd-program-data-and-e-12dd8779) — Source: Acumen Pharmaceuticals
- 2026-07-07 11:30 EST — [Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026](https://biopharmsignal.com/news/ABOS/acumen-pharmaceuticals-to-present-data-on-enhanced-brain-delivery-ebd-technology-95eca401) — Source: Acumen Pharmaceuticals
## Related News
- 2026-09-07 11:00 EST — ASND — [Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026](https://biopharmsignal.com/news/ASND/ascendis-to-share-its-latest-endocrinology-rare-disease-data-at-espe-2026-a501d9d2)
- 2026-09-07 07:53 EST — TEVA — [Teva Announces Launch of Offering of Senior Notes](https://biopharmsignal.com/news/TEVA/teva-announces-launch-of-offering-of-senior-notes-94143bde)
- 2026-09-06 05:00 EST — ROIV — [Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call](https://biopharmsignal.com/news/ROIV/roivant-to-present-topline-results-from-the-phase-2-phocus-study-of-mosliciguat--bf1ea553)
- 2026-09-04 20:30 EST — ORIC — [ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c--e23953dd)
- 2026-09-04 20:05 EST — RPID — [Rapid Micro Biosystems to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/RPID/rapid-micro-biosystems-to-participate-in-upcoming-investor-conferences-91a8800f)